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Abstract. The interaction between a bioactive molecule, 3-acetyl-4-oxo-6,7-dihydro-12H indolo-[2,3-a] 
quinolizine (AODIQ), with human serum albumin (HSA) has been studied using steady-state absorption 
and fluorescence techniques. A 1 : 1 complex formation has been established and the binding constant (K) 
and free energy change for the process have been reported. The AODIQ–HSA complex results in fluores-
cence resonance energy transfer (FRET) from the tryptophan moiety of HSA to the probe. The critical 
energy-transfer distance (R0) for FRET and the Stern–Volmer constant (Ksv) for the fluorescence quench-
ing of the donor in the presence of the acceptor have been determined. Importantly, KSV has been shown 
to be equal to the binding constant itself, implying that the fluorescence quenching arises only from the 
FRET process. The study suggests that the donor and the acceptor are bound to the same protein at dif-
ferent locations but within the quenching distance. 
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1. Introduction 
Fluorescence resonance energy transfer (FRET)1,2 is 
a distance-dependent interaction between the different 
electronic excited states of dye molecules in which 
excitation energy is transferred from one molecule 
(donor) to another molecule (acceptor) at the cost of 
the emission from the former molecular system. The 
process is also known as Förster’s resonance energy 
transfer (FRET). It is a powerful physical and/or 
biophysical technique that permits analysis of the in-
teraction between the fluorophores in proximity. 
FRET is an interaction that depends largely on the 
distance between the interacting partners. However, 
it is not the only factor influencing the efficiency of 
the energy transfer process. According to Förster’s 
theory, the efficiency of FRET depends principally 
on the following factors: (i) the extent of overlap be-
tween the donor emission and the acceptor absorp-
tion, (ii) the orientations of the transition dipoles of 
the donor and the acceptor, and (iii) the distance bet-
ween the donor and the acceptor.1,2 The lifetime of a 
fluorophore in the excited state is normally in the 
range of nanoseconds. After excitation, competition 
prevails between the various decay processes, namely, 
fluorescence and non-radiative deactivations, inclu-
ding energy transfer to the surrounding molecules. 
Efficiency of FRET is known to depend on the in-
verse sixth power of the intermolecular distance bet-
ween the donor and the acceptor molecules.1 
Because of the high sensitivity to the proximities of 
the interacting units in the nanometre range, people 
often use this technique for mapping cell surface pa-
rameters.3 The most widespread application of this 
phenomenon is its use as a spectroscopic ruler.1 
Most of the applications of the FRET phenomenon 
are in the field of biochemistry. It is an important 
technique for investigating a variety of biological 
phenomena including energy transfer processes.1,4,5 
One important consequence of such energy transfer 
is photosensitization, a classic example of which is 
photosynthesis.2 Further, FRET plays a key role in 
the photodynamic therapy (PDT) in cancer treat-
ment.1,2 It is also used extensively to study the struc-
ture, conformation, spatial distribution and assembly 
of complex proteins.5 The technique has also been 
exploited to locate the positioning of a fluorophore 
attached to a DNA.6 Since FRET is involved in a 
number of biological phenomena and/or used to 
study biological photoprocesses, interest has been 
paid to the studies of FRET from many fluorophores 
of biological interest in vitro. 
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 Human serum albumin (HSA) and bovine serum 
albumin (BSA), abundant in plasma, are the most 
widely studied transport proteins. The primary struc-
ture of HSA has about 580 amino acid residues and 
is characterized by low tryptophan content and high 
cystine content, stabilizing a series of nine loops. 
The secondary structure of this protein comprises 
67% of a helix of six turns and 17 disulphide 
bridges.7,8 The tertiary structure is composed of 
three domains I, II and III. Each domain is consti-
tuted by a cylinder formed by six helices, and each 
one of these domains is constituted by two sub-
domains formed by three helices that are covalently 
linked by a double-cystine bridge. These subdomains 
are named IA, IB, IIA, IIB, IIIA and IIIB.7,8 Since 
domains II and III share a common interface, bind-
ing of a probe to domain III leads to conformational 
changes affecting binding affinities to domain II. 
The tryptophan residue plays an important structural 
role in the formation of the IIA binding site by limit-
ing solvent accessibility. The molecular weight of 
HSA is 66⋅5 kD.8 HSA contains only one tryptophan 
residue (Trip-214). This tryptophan participates in 
additional hydrophobic packing interactions at the 
IIA–IIIA interface.7,8 
 It is well known that reactive oxygen species 
(ROS) participate in a number of pathological pro-
cesses in the nervous system.9 Compounds able to 
interfere with the action of ROS might be useful in 
prevention and treatment of these pathologies.10 Re-
cently, attention has been focussed toward designing 
and synthesizing compounds with a suitable spectrum 
of pharmacological and pharmaco-kinetic properties, 
among which indole derivatives are a distinct group 
with great potential. The indole nucleus seems to be 
a promising basic unit for designing and synthesis of 
new derivatives able to protect the nervous system.11 
Molecules containing the indole nucleus like β-
carbolines, carbazoles etc. are by now well establi-
shed as bioactive molecules.12–16 The single-step 
synthesis of 3-acetyl-4-oxo-6,7-dihydro-12H indolo-
[2,3-a] quinolizine (AODIQ) from 1-methyl-3,4-
dihydro-β-carboline leads to the assumption that the 
molecule should have biological activity.17 Through 
a series of experiments we have already established 
that the fluorophore molecule serves as an excellent 
fluorescent probe for biological systems.18–23 Given 
the broad range of biological activities of AODIQ, 
in the present study we have explored the FRET 
process operative between the tryptophan residue 
present in HSA and the AODIQ system in some de-
tail.  
2. Experimental  
3-Acetyl-4-oxo-6,7-dihydro-12H indolo-[2,3-a] qui-
nolizine (AODIQ) (figure 1) was synthesized in the 
laboratory using the method described earlier.17 It 
was purified by column chromatography and the  
purity of the product was checked by thin layer 
chromatography (TLC). The compound was further 
vacuum-sublimed before use. Triply distilled water 
was used for making the experimental solutions. 
HSA and HEPES buffer were purchased from 
Sigma–Aldrich, USA; 50 mM HEPES buffer solu-
tion was prepared in water and the pH was adjusted 
to 7⋅0 and was used in all the studies of AODIQ in 
protein. The absorption and fluorescence studies 
were performed using a Shimadzu MPS 2000 spec-
trophotometer and a Spex Fluorolog II spectro-
fluorimeter respectively.  
3. Results and discussion 
A prerequisite of a meaningful FRET investigation 
in a protein–probe system needs establishment of the 
stoichiometry of the protein:probe complex. Before 
going into the study of FRET we followed the fluo-
rescence behaviour of AODIQ with the addition  
of HSA in buffered aqueous medium (figure 2) to 
affirm the composition of the HSA–AODIQ com-
plex. There was no visible change in the absorption 
spectrum of AODIQ upon addition of HSA. On the 
contrary, there was a phenomenal change in the 
fluorescence profile. The broad emission band of the 
fluorophore showed a blue shift with an enhancement 
in the fluorescence yield. It was also associated with 
a narrowing in the full width half maximum 
(FWHM) of the emission band. The remarkable 
modification in fluorescence behaviour clearly indi-
cates interaction between fluorophore and protein.  
 The binding interaction was studied using the 
double reciprocal plot following the Benesi–
Hildebrand equation,24  
 
 
 
 
Figure 1. Structure of AODIQ. 
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where F0, Fx and F∞ are the integrated fluorescence 
intensities (areas under the fluorescence curves) of 
AODIQ considered in the absence of protein, at an 
intermediate protein concentration, and at a concen-
tration of complete interaction, respectively; K being 
the binding constant and [HSA] the protein concen-
tration.  
 A plot of (Fx–F0)
–1 against [HSA]–1 shows linear 
variation (figure 3) justifying the validity of the  
  
 
 
 
Figure 2. Emission spectra of AODIQ as a function of 
HSA concentration (λexc = 420 nm). Curves (i) → (xiii) 
correspond to 0, 10, 15, 20, 30, 35, 50, 60, 70, 80, 100, 
150, 220 μM HSA respectively. Inset shows the variation 
of fluorescence intensity as a function of HSA concentra-
tions.  
 
 
 
 
Figure 3. Double reciprocal plot for the complexation 
between AODIQ and HSA. 
Benesi–Hildebrand equation for the present case and 
hence confirms one-to-one stoichiometry for the 
probe : HSA complex. From the ratio of intercept to 
slope of the plot the binding constant has been deter-
mined to be 2⋅1 (±0⋅2) × 104 mol–1 dm3; which cor-
responds to a value of –24⋅9 kJ mol–1 dm3 for the 
free energy change (ΔG) of the complexation process.  
 The tryptophan moiety present in HSA absorbs 
appreciably at 280 nm giving a broad fluorescence 
with maximum at around 340–350 nm. The mole-
cule AODIQ does not absorb significantly at 280 nm 
but absorbs appreciably at 350 nm. The fluorescence 
of AODIQ in HSA environment has a maximum at 
488 nm. Considering the fluorescence band of tryp-
tophan and the absorption band of AODIQ, the pair 
was judged a suitable donor–acceptor system for the 
FRET study. On gradual addition of AODIQ, the 
fluorescence intensity of the tryptophan residue pre-
sent in the HSA decreased with concomitant in-
crease in the fluorescence intensity of AODIQ 
through an isoemissive point at 438 nm (figure 4).  
 Figure 4 reflects an efficient energy transfer from 
the tryptophan group residue present in HSA to 
AODIQ. That the complexation process is effective 
even in low concentration of HSA is reflected in the 
linearity of the Benesi–Hildebrand double reciprocal 
plot (figure 3) suggesting that the stoichiometry of 
the probe-HSA complex is 1 : 1. It is important to 
mention here that we observed neither any addi-
tional absorption band for the mixture of HSA and  
 
 
 
 
Figure 4. Fluorescence spectra of HSA as a function of 
AODIQ concentrations (λexc = 280 nm) in aqueous 
HEPES buffer solution. Curves (i) → (vi) correspond to 
0, 4⋅4, 6⋅5, 13⋅1, 17⋅4, 21⋅8 μM AODIQ concentrations.  
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AODIQ nor any deformity in the spectral pattern of 
the HSA–AODIQ system from that of the resultant 
of the individual absorption spectra corresponding to 
the donor and the acceptor taking into consideration 
the composition of the components in the mixture. 
Furthermore, the fluorescence spectrum of the mix-
ture of donor and acceptor did not show any addi-
tional new band other than the individual emission 
bands of the two components. These factors taken 
together negate the formation of any permanent 
ground-state complex between the donor–acceptor 
pair in the solution25–27 as well as the formation of 
exciplex between the excited donor and the unexci-
ted acceptor molecules. Thus the decrease in the 
fluorescence intensity of the donor with increasing 
acceptor concentration indicates a non-radiative en-
ergy transfer between the excited donor and the un-
excited acceptor.26,27 Furthermore, the excitation 
profile monitoring the emission of AODIQ (at 
488 nm) shows that in the presence of HSA, besides 
the S0 → S1 transition of AODIQ (λ exc
max ≈ 420 nm), a 
band with λ exc
max ≈ 280 nm (corresponding to the tryp-
tophan) appears. This provides strong evidence for 
the occurrence of Förster-type resonance energy 
transfer from the tryptophan moiety (donor) present 
in HSA to the AODIQ molecule (acceptor).21,27–29 
Consistent with the work of Lakowicz,1 Sengupta et 
al,30,31 De et al27 and our own laboratory,20,32 we  
assign the observation to an efficient Förster-type 
resonance energy transfer from the tryptophan moiety 
to the AODIQ system.  
 The quenching of the steady-state fluorescence of 
the donor (tryptophan) with the addition of acceptor 
(AODIQ) was followed by the Stern–Volmer equa-
tion: 
 F0/F = 1 + KSV [Q],  (2) 
where F0, F are the fluorescence intensities of the 
donor in the absence and in the presence of the ac-
ceptor molecule, [Q] is the acceptor concentration, 
and KSV is the Stern–Volmer constant for the fluo-
rescence quenching.  
 Figure 5 reveals that the Stern–Volmer plot is lin-
ear throughout the concentration range of the accep-
tor studied. The linearity of this plot proposes a 
single type of quenching process.1 The slope of the 
plot in figure 5 gives the Stern–Volmer constant 
(KSV) as 1⋅9 × 10
4 mol–1 dm3. Very good agreement 
between the two determined values, unequivocally 
confirms that KSV is nothing but the binding constant 
(K) itself and concludes that the fluorescence 
quenching results only from FRET. This further 
suggests that the donor (tryptophan) and the acceptor 
(AODIQ) are bound to the same protein at different 
locations but within quenching distance.  
3.1 Energy-transfer efficiency  
After establishing the occurrence of the FRET process 
in the HSA-AODIQ system, we intend to study the 
efficiency of the energy-transfer process between 
the two participating partners. Since AODIQ is a po-
tential candidate for PDT application, determination 
of the efficiency of the energy-transfer process gains 
importance. We have also determined the distance 
between the donor and the acceptor though there is 
an uncertainty in the distance measurement, arising 
principally due to the orientation factor, which is a 
major problem in exploiting this technique. Several 
methods have been proposed to overcome this pro-
blem.33,34 According to Förster’s non-radiative  
energy-transfer theory,35,36 the energy-transfer effi-
ciency E depends not only on the distance (r0) be-
tween the donor and the acceptor, but also on the 
critical energy transfer distance (R0) expressed by 
the following relation, 
 
 E = R0
6/(R0
6 + r0
6), (3)  
 
where R0 is the characteristic distance, called För-
ster’s distance or critical distance, at which the effi-
ciency of transfer is 50%. The magnitude of R0 is 
dependent on the spectral properties of the donor 
and the acceptor molecules. R0 is expressed as fol-
lows  
 
 R0
6 = 8⋅8 × 1023 [κ2n–4φDJ(λ)] in Å
6, (4) 
 
 
 
 
Figure 5. Stern–Volmer plot for the quenching of fluo-
rescence of HSA by AODIQ in HEPES buffer solution.  
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where κ2 is the factor expressing the relative orienta-
tion of the donor to the acceptor molecule, n is the 
refractive index of the medium, φD is the quantum 
yield of the donor (0⋅14)2 in the absence of the  
acceptor and J(λ) is the overlap integral of the fluo-
rescence emission spectrum of the donor and the ab-
sorption spectrum of the acceptor in units of  
M–1 cm3. The spectral overlap integral J(λ) was cal-
culated by numerical integration method. The over-
lap integral J(λ) for a donor-acceptor pair is defined 
as,1,27,37 
 
 4
0
( ) ( ) ( ) d ,
D A
J Fλ λ ε λ λ λ
∞
= ∫  (5) 
 
where FD(λ) is the corrected fluorescence intensity 
of the donor at wavelengths λ to (λ + Δλ), with the 
total intensity normalized to unity and εA(λ), the  
molar extinction coefficient of the acceptor at wave-
length λ. The overlap spectrum is shown in figure 6.  
 Förster’s distance (R0) has been calculated assum-
ing random orientation of the donor and acceptor 
molecules. Thus, from (4), we have calculated R0 to 
be 73⋅6 Å taking κ2 = 2/3, n = 1⋅333 (water), φD = 
0⋅14.2 
 The excellent correlation between the determined 
values of Stern–Volmer constant (KSV) and binding 
constant (K) indicates that the energy transfer effi-
ciency (E) between the two interacting partners in 
the present case is ≈100%. The dimension of HSA, a 
66kD protein may not be more than 20 Å. Consider-
ing this value for r0, 74 Å for R0 as estimated above 
and using (3), we get an estimate of E as 0⋅9996. 
This is consistent with the agreement between the 
 
 
 
 
Figure 6. Overlap of fluorescence spectrum of HSA 
(solid line) and absorption spectrum of AODIQ (dotted 
line). 
values of KSV and K. This implies that the donor 
(tryptophan part of the HSA) and the acceptor 
(AODIQ) are bound to the same protein at different 
locations but within quenching distance.  
4. Conclusion 
The present photophysical study of HSA and AODIQ 
system in buffered aqueous environment leads to the 
following propositions. There is interaction between 
the probe and the albumin protein. A probe–HSA 
complex is formed with a 1 : 1 stoichiometry. For-
mation of the probe–HSA complex leads to efficient 
energy transfer from the tryptophan moiety of HSA 
to AODIQ. The quenching of the donor (HSA) fluo-
rescence in the presence of the acceptor (AODIQ) is 
assigned completely to the FRET process.  
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